据记者张国民报道,记者日前从国家食品药品监督管理局获悉,我国具有自主知识产权的抗体类治疗肝癌新药———碘[131I]美妥昔单抗注射液,日前获得国家食品药品监督管理局颁发的生产批件,即将于近期上市。这是全球第一个专门用于治疗原发性肝癌的单抗导向同位素药物。1987年,在科 According to a reporter Zhang Guomin, the reporter recently learned from the State Food and Drug Administration that China has an independent intellectual property rights of antibodies for the treatment of hepatotoxicity --- iodine [131I] metribuzumab injection, recently received the State Food and Drug Administration The production approval document issued by the Bureau is about to be listed soon. This is the world’s first MAb-targeted isotope drug designed to treat primary liver cancer. In 1987, in the section